Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Humacyte (NASDAQ:HUMA) and maintained a price target of $13.
September 20, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Humacyte, maintaining a $13 price target. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $13 by a reputable analyst suggests positive sentiment and potential for stock appreciation. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100